News | Molecular Imaging | March 02, 2017

Gamma Medica Expands Into European Breast Imaging Market

Partnership with medical supplies distributor enables women in the United Kingdom, Ireland and Channel Islands access to LumaGEM Molecular Breast Imaging for secondary breast cancer screening

Gamma Medica, European breast imaging market, LumaGem MBI, molecular breast imaging, Hospital Services Limited

March 2, 2017 — Gamma Medica announced it has partnered with Hospital Services Limited (HSL), a Dublin, Ireland-based established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system in the United Kingdom, Ireland and the Channel Islands.

Women are eligible for the United Kingdom’s National Health Service (NHS) breast screening program at age 50-79 years, with women being invited to be screened every three years. Similarly in Ireland, women 50-69 years old are eligible for breast screenings every two years. Dense breast tissue not only increases the risk of developing breast cancer, but decreases the visibility of a cancer on conventional mammograms and other forms of anatomical imaging devices. Dense breast tissue and cancer both appear white on mammograms, making it difficult to distinguish between the two. This may lead to false negatives, unwarranted biopsies or delayed diagnoses.

Ideal for dense breast tissue, MBI significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective as a secondary screening method compared to ultrasound or magnetic resonance imaging (MRI), with far fewer false positives. Peer-reviewed clinical research reports the use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities. MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI.

A retrospective study, which complemented earlier published prospective clinical research, was published in the American Journal of Roentgenologys August 2016 issue. This retrospective study monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent were invasive and node negative, indicating they were detected at an early stage and therefore presented the patient with the likelihood of a better prognosis.

For more information: www.gammamedica.com

Related Content

Norwegian Study Confirms Benefits of Pressure-Based Breast Compression for Mammography
News | Mammography | May 22, 2017
Sigmascreening recently announced that a large independent Norwegian study further confirms Sigma’s hypothesis that...
Neiman Institute Releases Breast Screening Bundle Tool
News | Business | May 22, 2017
A new free resource allows radiology practices to estimate professional, technical and global bundled prices for breast...
Seno Medical's Imagio Opto-Acoustic Breast Imaging System Proves Strong Predictor of Malignancy
News | Breast Imaging | May 16, 2017
Seno Medical Instruments Inc. recently announced that is Imagio opto-acoustic (OA/US) breast imaging system results...
Arkansas Surgeon Reports Positive Findings From Use of BioZorb 3-D Marker
News | Radiation Therapy | May 12, 2017
A new research study concluded that use of the BioZorb surgical marker appears to provide better cosmetic outcomes and...
mammography exam

Photo courtesy of Hologic

News | Women's Health | May 11, 2017
Breast cancer is one of the leading causes of death of women worldwide. In Canada, according to the Canadian Cancer...
ABUS

Photo courtesy of GE Healthcare

Feature | Women's Health | May 05, 2017 | By Jeff Zagoudis
Over the last decade, the impact of dense fibroglandular breast tissue on breast cancer screening has become a...
U.S. Clinical Data Supports Echotherapy With Echopulse for Breast Fibroadenomas
News | Focused Ultrasound Therapy | May 04, 2017
Theraclion recently announced the presentation of data from the U.S. feasibility trial of echotherapy with Echopulse, a...
Three-Week Radiation Therapy Treatment Post-Mastectomy Safe and Effective
News | Radiation Therapy | May 02, 2017
A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and...
Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System
News | Brachytherapy Systems, Women's Healthcare | May 01, 2017
iCAD Inc. announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation...
Overlay Init